#Israel #Ness Zion #Matricelf #FDA feedback #NewRal

Matricelf Secures FDA Approval for Innovative Trial Design

Matricelf Ltd., a pioneering company in regenerative medicine, has made significant strides in its efforts to advance a groundbreaking treatment for spinal cord injuries. On September 3, 2026, Matricelf announced that it has successfully received written feedback from the U.S. Food and Drug Administration (FDA). This vital communication supports several key components of the proposed design for their first human clinical trial involving NewRal, Matricelf's investigational personalized neural tissue transplant.

Understanding NewRal

NewRal is designed to provide a novel method for treating patients who have suffered traumatic spinal cord injuries. The approach employs autologous neural tissue transplants, which means that the tissue used for transplantation is derived from the patients themselves. This technique not only enhances the likelihood of compatibility but also minimizes the risk of rejection by the immune system.

The clinical trial is specifically aimed at adult patients diagnosed with chronic, complete traumatic thoracic spinal cord injuries classified as American Spinal Injury Association (ASIA) Impairment Scale (AIS) A. Matricelf's CEO, Gil Hakim, expressed optimism about the FDA's supportive feedback, which signifies critical alignment between regulatory authorities and the company's clinical aspirations.

Key Aspects of the FDA’s Feedback

The FDA's response, delivered through a Written Response Only (WRO) interaction, indicates their agreement with several essential elements of the proposed clinical trial:

• - Patient Population: The FDA supports the focus on adult patients with chronic, complete thoracic injuries, identifying it as a justified demographic for this trial.
• - Trial Design: The open-label, single-arm trial format, coupled with an initial follow-up period of 12 months, was deemed appropriate for assessing safety and patient tolerability.
• - Clinical Assessments: Proposed primary safety assessments and exploratory efficacy measures were acknowledged by the FDA, noting the relevancy of tools such as the ISNCSCI, MAS, and SCIM III for evaluating neurological changes and functional independence.

While the FDA's feedback marks a pivotal moment for Matricelf, it did come with further requests for information. As the company prepares its Investigational New Drug (IND) application, it must address additional elements including trial stopping rules, objective discharge criteria, and surgical procedure details.

Continuing the Journey

This written guidance positions Matricelf favorably as it continues to develop NewRal and move forward with clinical preparations. The FDA's agreement on several key elements of the trial offers a reassuring endorsement, prompting the company to integrate the feedback into their ongoing processes. Gil Hakim emphasized the importance of this endorsement, stating, “The FDA’s feedback is a crucial step for us as we prepare for the looming IND submission.”

The Future of NewRal

The development of NewRal is still categorized as investigational and has yet to receive approval from the FDA or any other regulatory bodies, emphasizing its status as an experimental therapy. Matricelf’s innovative approach combines patient-derived cellular components, including induced pluripotent stem cells, with a biomaterial scaffold customized from the patient’s own tissue, creating a promising path toward recovery of neural functions post-injury.

Matricelf, publicly traded on the Tel Aviv Stock Exchange under the symbol MTLF, is inspired by research from Tel Aviv University, consolidating the company's position in the cutting-edge arena of personalized medicine. The future of NewRal holds great promise as it continues to navigate the complexities of clinical trials, regulatory reviews, and the pursuit of effective spinal cord injury treatments. With the positive momentum from the FDA, Matricelf might soon find itself at the forefront of transformative therapies, capable of changing lives for those affected by devastating spinal conditions.